View in EDS

BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?

Saved in:

Bibliographic Details
Title:	BRAF mutation and neoadjuvant chemo-immunotherapy, is it worthwhile?
Authors:	Gallina FT; Thoracic Surgery Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy; Tumor Immunology and Immunotherapy Unit, IRCCS 'Regina Elena' National Cancer Institute, Rome, Italy. Electronic address: filippo.gallina@ifo.it., Cecere FL; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Bergomi S; Division of Nuclear Medicine, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Buglioni S; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Visca P; Department of Pathology, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Landi L; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy., Cappuzzo F; Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
Source:	Lung cancer (Amsterdam, Netherlands) [Lung Cancer] 2025 May; Vol. 203, pp. 108514. Date of Electronic Publication: 2025 Apr 03.
Publication Type:	Letter
Journal Info:	Publisher: Elsevier Scientific Publishers Country of Publication: Ireland NLM ID: 8800805 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-8332 (Electronic) Linking ISSN: 01695002 NLM ISO Abbreviation: Lung Cancer Subsets: MEDLINE; In Process
Database:	MEDLINE Ultimate

Description
ISSN:	1872-8332
DOI:	10.1016/j.lungcan.2025.108514